| Literature DB >> 25931286 |
Aaron M Udager1, Delphine C M Rolland1, Jonathan B McHugh1, Bryan L Betz1, Carlos Murga-Zamalloa1, Thomas E Carey2, Lawrence J Marentette2, Mario A Hermsen3, Kathleen E DuRoss1, Megan S Lim1, Kojo S J Elenitoba-Johnson1, Noah A Brown1.
Abstract
Inverted sinonasal papilloma (ISP) is a locally aggressive neoplasm associated with sinonasal squamous cell carcinoma (SNSCC) in 10% to 25% of cases. To date, no recurrent mutations have been identified in ISP or SNSCC. Using targeted next-generation sequencing and Sanger sequencing, we identified activating EGFR mutations in 88% of ISP and 77% of ISP-associated SNSCC. Identical EGFR genotypes were found in matched pairs of ISP and associated SNSCC, providing the first genetic evidence of a biologic link between these tumors. EGFR mutations were not identified in exophytic or oncocytic papillomas or non-ISP-associated SNSCC, suggesting that the ISP/SNSCC spectrum is biologically distinct among sinonasal squamous tumors. Patients with ISP harboring EGFR mutations also exhibited an increased progression-free survival compared with those with wild-type EGFR. Finally, treatment of ISP-associated carcinoma cells with irreversible EGFR inhibitors resulted in inactivation of EGFR signaling and growth inhibition. These findings implicate a prominent role for activating EGFR mutations in the pathogenesis of ISP and associated SNSCC and rationalize consideration of irreversible EGFR inhibitors in the therapy of these tumors. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25931286 PMCID: PMC4508878 DOI: 10.1158/0008-5472.CAN-15-0340
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701